Botanical drug curcumin oral oropharyngeal cancers

Dental Tribune International

Tue. 25. February 2020

save

LOS ANGELES, U.S.: In a recent study, researchers examined the effect that APG-157, a botanical plant-based drug that contains curcumin and was developed under the U.S. Food and Drug Administration’s Botanical Drug Development: Guidance for Industry, has on neck and head cancer patients. The findings showed that the drug helps patients fight oral and oropharyngeal cancers by reducing the concentration of cytokines in the saliva and could serve as a therapeutic drug in combination with immunotherapy.

According to Cancer.Net, head and neck cancers account for approximately 4% of all cancers and an estimated 650,000 new cases will be reported this year. Since current treatment options, such as surgery, radiation and chemotherapy, often cause adverse effects, there is a strong need for novel low-toxicity therapies for the effective treatment of cancer patients.

Curcumin is a medicinally active drug. Owing to its antioxidant properties and its ability to reduce swelling and inflammation, curcumin has been proved to help fight multiple cancers. When taken orally, the drug is poorly absorbed into the bloodstream. However, a recent study found that, when APG-157 was administered by oral mucosal absorption, levels of curcumin circulating in the blood were high and it ended up being absorbed by cancer tissue.

In the study, researchers from the University of California, Los Angeles Jonsson Comprehensive Cancer Center compared the effect of APG-157 in 12 participants who had oral and oropharyngeal cancer with a control group of 13 participants who did not have cancer. The medication was administered every hour for 3 hours, and the researchers collected blood and saliva samples before administering the medication and 24 hours after the last dosage.

The researchers found that the therapy was successful in reducing the relative abundance of Bacteroides species, a group of Gram-negative bacteria that is associated with oral cancer. Additionally, APG-157 helped attract immune system T cells to the tumor area. This suggests that, when used in combination with immunotherapy drugs, the therapy could help the immune system T cells both recognize and kill tumors. Since it has the potential to hinder the growth of Bacteroides species, the researchers believe that APG-157 could also improve cancer therapy through oral microbial changes.

“Dental professionals are likely to be the first to identify suspicious lesions in the oral cavity, and this provides a valuable mechanism for screening. Treatment for oral cancer is much more successful when cancers are diagnosed at an early stage, so dental professionals are key to early diagnosis of oral cancers,” co-author Dr. Marilene Wang told Dental Tribune International.

The researchers are now planning a Phase 2 trial of APG-157, in which they will study the effect of the drug when given on a longer-term basis and to a larger number of oral cancer patients. They hypothesize that APG-157 will be able to suppress the growth of oral cancer.

The study, titled “A randomized, phase 1, placebo‐controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor‐associated microbes,” was published online on Feb. 5, 2020, in Cancer, ahead of inclusion in an issue.

Tags:

To post a reply please login or register

Curcumin holds promise in treating oral disease and cancers

BARI, Italy: An increasing number of products are appearing on the market aimed at replacing toothpastes and mouthrinses containing synthetic constituents ...

Award-winning seaweed drug helps fight disease

CARDIFF, UK: Together with Norwegian biopharmaceutical company AlgiPharma, researchers at Cardiff University have been working on new drugs to combat ...

Toothpaste ingredient triclosan may help fight drug-resistant malaria

MANCHESTER/CAMBRIDGE, UK: Over half a million deaths per year result from malaria, caused by parasites of the genus Plasmodium, and with increasing ...

Researchers conduct large study into oropharyngeal cancers

NEW YORK, U.S.: In the largest study of its kind, researchers from the Dana-Farber/Brigham and Women’s Cancer Center (DFBWCC) have sifted through the ...

Dual-light photodynamic therapy helps kill oral bacteria

ESPOO, Finland: Regular toothbrushing helps maintain good oral health, but does not completely prevent the occurrence of oral disease. To help kill ...

Finnish study finds oral health worse in oropharyngeal cancer patients with HPV than oral tongue cancer patients

HELSINKI, Finland: Human papillomavirus (HPV) causes roughly 2% of oral cavity or laryngeal cancers and 31% of oropharyngeal cancers, according to a Lancet ...

Cancer drug may help treat human papillomavirus infections, study finds

BIRMINGHAM, Ala, U.S.: Known to cause several cancers, human papillomaviruses (HPV) are contracted by around 12,000 people—aged between 15 and 24—each ...

Mobile phones might help improve oral health in children and adolescents

LONDON, UK: Nowadays, the majority of people, even at a young age, own a mobile phone, making them a wide-reaching tool for interventions. For some time ...

Robotic surgery improves health outcomes in oropharyngeal cancer patients

LOS ANGELES, U.S.: Owing to its considerable benefits, including being minimally invasive, robot-assisted surgery is gaining increasing recognition in many ...

Review offers evidence of link between oral microbiome and cancer

SOLNA, Sweden: The oral cavity represents a complex microenvironment where a diverse microbial community flourishes. A recent review study, carried out by ...

Education

Live webinar
Wed. 16 October 2024
8:10 am EST (New York)